Gufic Biosciences: AGM on Sept 4, Book Closure Aug 29-Sept 4 for Dividend
Gufic Biosciences will hold its 42nd AGM on September 4, 2026, via VC/OAVM. The company proposes a final dividend of 10% (₹0.10 per share) for FY2026, subject to approval. Book closure for AGM and dividend payment is from August 29 to September 4, 2026, with a record date of August 28, 2026.
The announcement details the AGM schedule and dividend proposal, which are important for shareholders. The book closure dates are also critical for determining eligibility for the dividend and attending the AGM, impacting shareholders directly.
The announcement is routine in nature, providing information about the upcoming AGM, book closure dates, and a proposed dividend. It does not contain any significant new financial performance data or strategic shifts that would warrant a positive or negative sentiment.
Gufic Biosciences Limited has announced that its 42nd Annual General Meeting (AGM) will be held on Friday, September 04, 2026, at 3:30 p.m. IST via Video Conferencing (VC) / Other Audio Visual Means (OAVM). The meeting will address ordinary and special businesses as detailed in the notice dated July 31, 2026.
Furthermore, the company's Register of Members and Share Transfer Books will be closed from Saturday, August 29, 2026, to Friday, September 04, 2026, inclusive. This closure is for the purpose of the AGM and the payment of a final dividend for the financial year ended March 31, 2026, subject to shareholder approval at the AGM. The record date for this purpose is Friday, August 28, 2026.
The proposed final dividend is 10%, amounting to ₹0.10 per equity share of face value ₹1. The AGM agenda also includes the adoption of audited standalone and consolidated financial statements for FY2026, the appointment of a director, ratification of cost auditors' remuneration, and the re-appointment of Mr. Pankaj J. Gandhi as Whole Time Director for a further period of five years from September 07, 2026, to September 06, 2031.
What to do with a filing like this
Gufic Biosciences Limited filed this with the NSE as a statutory disclosure, categorised under agm. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Gufic Biosciences Limited. Read the original for the full detail.